Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Osnuvo, with its active ingredient Teriparatide, is a groundbreaking treatment for osteoporosis in men and postmenopausal women at high risk for fracture. Teriparatide is a recombinant form of parathyroid hormone that works primarily by stimulating new bone formation. Unlike other treatments that merely slow the progression of bone loss, Osnuvo actively works to rebuild bone and significantly reduce the risk of fractures. This medication is particularly suited for individuals who have had a fracture related to osteoporosis or those who are intolerant or unresponsive to other osteoporosis medications.
Before you buy Osnuvo, it is crucial that you talk to your healthcare provider about potential side effects and teriparatide injection price.
| Fact Table | |
|---|---|
| Formula | C181H291N55O51S2 |
| License | FDA Approved |
| Bioavailability | 95% (subcutaneous injection) |
| Legal status | Prescription Drugs |
| Chemical Name | Teriparatide |
| Elimination half-life | 1 hour |
| Dosage (Strength) | 20 mcg/day via subcutaneous injection |
| Pregnancy | Not recommended |
| Brands | Osnuvo |
| Protein binding | Not significant |
| PubChem CID | 16132304 |
| MedlinePlus | a603013 |
| ChEBI | CHEBI:63591 |
| ATC code | H05AA02 |
| DrugBank | DB06285 (Teriparatide) |
| KEGG | D05498 (Teriparatide) |
| Routes of administration | Subcutaneous injection |
Osnuvo is administered as a daily subcutaneous injection. Patients are typically prescribed a 20 microgram dose per day, delivered via a pre-filled pen that can be used for up to 28 days. It is recommended to inject Osnuvo into the thigh or abdominal area. Prior to starting treatment, it is crucial for patients to receive proper training from healthcare professionals on how to safely and effectively administer the injection.
The active ingredient in Osnuvo is Teriparatide.
Teriparatide has been associated with an increased risk of osteosarcoma in rat studies. Although this has not been observed in humans, Osnuvo should be used with caution in patients with an increased baseline risk of osteosarcoma.
Avoid using Osnuvo in individuals with hypercalcemia, metabolic bone diseases other than osteoporosis, or severe renal impairment.
Osnuvo is not recommended during pregnancy or breastfeeding due to potential adverse effects on fetal development.
The safety and efficacy of teriparatide have not been established in pediatric patients and its use is not recommended.
Digoxin: Teriparatide injection can cause transient increases in serum calcium levels, potentially leading to digoxin toxicity in patients using cardiac glycosides.
Diuretics: Concurrent use with thiazide diuretics may increase the risk of hypercalcemia.
Anti-Seizure Medications: Medications that alter bone metabolism, such as anticonvulsants, may diminish the efficacy of Osnuvo.
While Osnuvo is an effective treatment for osteoporosis, it can cause side effects, including but not limited to nausea, leg cramps, dizziness, headache, pain at the injection site.
What is Osnuvo?
Osnuvo is a brand name for teriparatide, a medication used to treat osteoporosis in men and postmenopausal women who are at high risk for fractures. It is a recombinant form of parathyroid hormone, which helps to stimulate new bone growth and increase bone density.
How to take Osnuvo?
Osnuvo is administered as a subcutaneous injection, usually once a day. It is important to follow the dosing instructions provided by your healthcare provider. Typically, the injection is given in the thigh or abdomen.
How is teriparatide administered?
Teriparatide is administered as a subcutaneous injection. Patients are usually instructed to inject themselves once daily. The injection should be administered in the thigh or abdomen.
Is teriparatide a bisphosphonate?
No, teriparatide is not a bisphosphonate. Bisphosphonates work by inhibiting bone resorption, whereas teriparatide stimulates bone formation by acting as an analog of parathyroid hormone.
Is teriparatide a steroid?
No, teriparatide is not a steroid. It is a synthetic form of parathyroid hormone used to treat osteoporosis by stimulating new bone growth.
Is teriparatide safe?
Teriparatide is considered safe when used as prescribed, but it can have side effects. The safety and effectiveness of teriparatide have been evaluated in clinical trials. It is generally prescribed for up to 2 years of use, as long-term safety data beyond this period are not well established.
What are the side effects of teriparatide?
Common side effects of teriparatide may include:
Rare but serious side effects can include:
How to inject teriparatide?
To inject teriparatide:
Where to inject teriparatide?
Teriparatide should be injected into the subcutaneous tissue, usually in the thigh or abdomen. It is important to rotate injection sites to avoid lipodystrophy (changes in fat tissue).
